It has been reported that Yupingfengsan can treat ALI by inhibiting TLR4/MyD88 signal pathway and reducing the expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α (57). Here, MYD88 is linked to acute respiratory distress syndrome.